Download PDF
Thromb Haemost 2002; 88(03): 387-388
DOI: 10.1055/s-0037-1613227
In Focus
Schattauer GmbH

Venous Thrombosis Following the Use of Intermediate Purity FVIII Concentrate to Treat Patients with Von Willebrand’s Disease

M. Makris
1   Sheffield Haemophilia and Thrombosis Cetre
,
B. Colvin
2   The Royal London Hospital Comprehensive Hamophilia Centre
,
V. Gupta
2   The Royal London Hospital Comprehensive Hamophilia Centre
,
M. L. Shields
3   Hull Royal Infirmary Haemophilia Centre
,
M. P. Smith
4   St Thomas’ Hospital Comprehensive Haemophilia Centre, London, U.K
› Author Affiliations
Further Information

Publication History

Received 20 April 2002

Accepted after revision 20 June 2002

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

We describe four patients with von Willebrand’s disease (VWD) who experienced venous thrombosis after treatment with an intermediate purity factor VIII (FVIII) concentrate (Haemate P®) was used to cover invasive or surgical procedures. Most patients had additional risk factors for venous thromboembolism (VTE) and it is difficult to be certain of the contribution of the concentrate to the VTE. In view of the recognised association between high factor VIII activity (FVIII:C) levels and VTE there is a physiological basis for this complication and it is important to consider this when administering FVIII containing concentrates to VWD patients.

Keywords

Thrombosis - concentrate - VWD
 

  • References

  • 1 Kasper CK. Postoperative thrombosis in haemophilia B. N Engl J Med 1973; 289: 160.
    PubMedGoogle Scholar
  • 2 Hough RE, Hampton KK, Preston FE, Channer KS, West J, Makris M. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors. Br J Haematol 2000; 111: 974-9.
    PubMedGoogle Scholar
  • 3 Lowe GD. Factor IX and thrombosis. Br J Haematol 2001; 115: 507-13.
    CrossrefPubMedGoogle Scholar
  • 4 Bolton-Maggs PH, Colvin BT, Satchi BT, Lee CA, Lucas GS. Thrombogenic potential of factor XI concentrate. Lancet 1994; 344: 748-9.
    PubMedGoogle Scholar
  • 5 Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, Retzios AD, Kapelan BA, Schwartz RS, Kessler C. and the Alphanate Study Group. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicentre study. Blood 2002; 99: 450-6.
    CrossrefPubMedGoogle Scholar
  • 6 Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 1995; 345: 152-5.
    CrossrefPubMedGoogle Scholar
  • 7 O’Donnell J, Laffan M. Elevated plasma factor VIII levels – a novel risk factor for venous thromboembolism. Clin Lab 2001; 47: 1-6.
    PubMedGoogle Scholar